These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20974239)

  • 1. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
    Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
    Int J Pharm; 2011 Jan; 403(1-2):130-5. PubMed ID: 20974239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
    J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process.
    Park JH; Chi SC; Lee WS; Lee WM; Koo YB; Yong CS; Choi HG; Woo JS
    Arch Pharm Res; 2009 Jan; 32(1):139-48. PubMed ID: 19183887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
    Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
    Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
    J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
    Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
    Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
    Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
    Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
    Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
    Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
    Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.
    Lee JY; Kim KS; Kang YM; Kim ES; Hwang SJ; Lee HB; Min BH; Kim JH; Kim MS
    Int J Pharm; 2010 Jun; 392(1-2):51-6. PubMed ID: 20298770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
    Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
    Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
    Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
    J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process.
    Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
    Drug Dev Ind Pharm; 2011 Jun; 37(6):628-37. PubMed ID: 21401339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
    Kim SC; Kim DW; Shim YH; Bang JS; Oh HS; Wan Kim S; Seo MH
    J Control Release; 2001 May; 72(1-3):191-202. PubMed ID: 11389998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
    Harper E; Dang W; Lapidus RG; Garver RI
    Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
    Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
    Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo.
    Zhu Z; Li Y; Li X; Li R; Jia Z; Liu B; Guo W; Wu W; Jiang X
    J Control Release; 2010 Mar; 142(3):438-46. PubMed ID: 19896997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.